Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
Go back to Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 50.22 -0.84 (1.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $51.06 | 52 Week High | $45.58 | |||
| Open | $50.20 | 52 Week Low | $37.82 | |||
| Day High | $50.33 | P/E | N/A | |||
| Day Low | $49.50 | EPS | $0.00 | |||
| Volume | 4,709,246 | |||||
